Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price dropped 6.3% during trading on Monday . The company traded as low as $48.24 and last traded at $49.15, with a volume of 425,403 shares traded. The stock had previously closed at $52.44.

FPRX has been the topic of a number of research reports. BMO Capital Markets initiated coverage on Five Prime Therapeutics in a report on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price objective on the stock. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Five Prime Therapeutics in a report on Monday, April 18th. Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 20th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research report on Sunday, May 8th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research report on Sunday, May 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $52.33.

The stock has a 50 day moving average price of $45.00 and a 200 day moving average price of $40.69. The company has a market capitalization of $1.28 billion and a PE ratio of 5.35.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. During the same quarter last year, the firm earned ($0.45) EPS. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. The company’s revenue for the quarter was up 46.1% on a year-over-year basis. Equities analysts forecast that Five Prime Therapeutics Inc. will post ($2.35) EPS for the current fiscal year.

In other news, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $50.77, for a total transaction of $25,385.00. Following the transaction, the director now owns 500 shares in the company, valued at approximately $25,385. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total value of $603,652.50. Following the transaction, the director now owns 12,195 shares in the company, valued at approximately $603,652.50. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. RS Investment Management Co. LLC acquired a new position in Five Prime Therapeutics during the fourth quarter valued at $21,214,000. Marshall Wace LLP boosted its position in Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock valued at $9,841,000 after buying an additional 71,262 shares during the period. Russell Frank Co acquired a new position in Five Prime Therapeutics during the fourth quarter valued at $1,265,000. Finally, California State Teachers Retirement System boosted its position in Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock valued at $1,744,000 after buying an additional 2,842 shares during the period.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.